药用辅料市场－全球产业规模、份额、趋势、机会及预测（依产品、功能、剂型、地区及竞争格局划分，2021-2031年）

全球药用辅料市场预计将从 2025 年的 89.7 亿美元成长到 2031 年的 121.9 亿美元，复合年增长率为 5.25%。

这些药理学上惰性的物质与活性成分配製在一起，以促进药物递送、提高稳定性并确保剂量均匀性。市场成长的主要驱动力是慢性病盛行率的上升和全球人口老化，这推动了对大规模生产的固态剂型的需求。此外，学名药产业的持续扩张也是推动销售成长的关键因素。根据美国可及药品协会（Association for Accessible Medicines）预测，到2024年，学名药和生物相似药将占美国处方处方笺的90%，这表明经济有效的治疗方法在推动原料药需求方面发挥关键作用。

阻碍市场扩张的一大挑战是监管合规和供应链透明度日益复杂的问题。製造商必须遵守严格的杂质含量标准，这需要进行广泛的风险评估和原材料可追溯性管理。这些严格的要求往往会导致营运成本增加和核准流程冗长，给供应商带来障碍，他们必须投入大量资金才能满足世界各地卫生监管机构不断变化的安全标准。

市场驱动因素

生物製药製造业的快速扩张推动了对高纯度、功能性辅料的需求，这些辅料对于肠外给药至关重要。生物製药，例如单株抗体，需要特殊的稳定剂和界面活性剂来维持其分子结构，这使得市场关注点从传统的固态製剂填充剂转向了先进的製剂成分。这种向复杂治疗方法的结构趋势正在迅速加速。根据2024年9月发布的CPHI 2024年度报告，该产业正处于一个转折点，预计复杂分子药物的核准核准将超过小分子药物。 2023年核准的55种新药中，有17种是生物製药，9种是胜肽类或寡核苷酸疗法，这便是一个例证。这项创新得到了大量资金的支持；根据欧洲製药工业协会联合会（EFPIA）估计，2024年欧洲以研发为基础的製药业将在研发方面投入约550亿欧元，这将直接推动这些新型药物递送系统的开发平臺。

随着製药公司越来越多地将生产外包以优化成本并获取专业技术，医药契约製造市场的扩张也推动了成长。合约研发生产机构（CDMO）作为中央采购机构的角色日益强化，它们需要大量符合多种标准的辅料以满足不同的国际监管标准。这种采购集中化也体现在主要服务供应商的财务表现中。根据龙沙公司于2024年3月发布的2023年度报告，该公司销售额达67亿瑞士法郎，年增7.9%，主要得益于其生物製剂和小分子药物部门的强劲表现。随着CDMO扩大营运规模，它们需要可靠的、用途广泛的辅料供应链，以实现各种剂型的高效生产。

市场挑战

对监管合规性和供应链透明度日益增长的要求，对全球药用辅料市场构成了重大阻碍因素。随着国际卫生机构对杂质含量实施更严格的限制，并要求原料可追溯性，辅料生产商的工作量急剧增加。这种合规压力迫使供应商将大量资源投入持续的风险评估和验证通讯协定中，而不是扩大产能。因此，将合规原料推向市场所需的时间和资金都在增加，这造成了许多障碍，对小规模供应商的影响尤其严重，并降低了整个供应链的流动性。

这些监管瓶颈直接阻碍了市场成长，扰乱了基本药物原料的供应，导致生产中断。据美国卫生系统药剂师协会 (ASHP) 称，到 2024 年，美国医疗保健行业报告的药品短缺数量将达到创纪录的 323 种，这场危机部分归因于持续存在的生产品质挑战和监管障碍。下游製造业的这种不稳定性限制了对辅料的稳定需求，因为成品製造商在合规性问题日益增多的情况下无法维持稳定的生产计划。

市场趋势

随着越来越多的生产商寻求简化口服固体製剂的生产流程并降低配方复杂性，多功能和共加工辅料的应用正在加速。先进的预配方系统，例如即用型薄膜包衣和高级粘合剂，无需多阶段混合工艺，从而提高了运营效率并最大限度地减少了批次间差异。这种对生产优化的追求正促使主要供应商扩大生产规模，以确保这些关键成分的稳定供应。根据2025年7月《印度化学新闻》一篇报导「Colorcon在马来西亚开设新的薄膜包衣生产工厂」的文章报道，该公司开设了一座占地20万平方英尺的新生产工厂，以满足该地区对先进包衣系统和功能性辅料日益增长的需求。

同时，受患者对非动物性配方偏好的转变以及严格的饮食限制的推动，市场正经历着向植物来源、洁净标示成分的重大转变。这一趋势迫使辅料供应商从传统的动物性成分（例如明胶）转向纤维素替代品（例如羟丙基纤维素，HPMC），这些替代品性能相当，但更易于被消费者接受。为了体现这项策略调整，该公司宣布分阶段投资2亿美元，新建一座能够生产适合素食者的硬壳胶囊的工厂，以满足北美市场对空胶囊洁净标示製剂形式日益增长的需求。这项消息已在2025年10月发表于《营养展望》杂誌的一篇文章中披露，该文章报导「ACG将投资2亿美元建设美国首个空胶囊生产工厂」。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球药用辅料市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品种类（有机化学品、油脂化学品（脂醇类、金属硬脂酸盐、甘油等）、碳水化合物（糖、醇、淀粉）、石油化学品、蛋白质、磷酸钙、金属氧化物、盐、碳酸钙、硫酸钙等）
  • 依功能分类（填充剂/稀释剂、悬浮剂/黏度调节剂、包衣剂、粘合剂、调味剂/甜味剂、崩坏、着色剂、润滑剂/滑移剂、防腐剂、乳化剂、其他）
  • 依剂型分类（口服製剂、锭剂、胶囊（硬胶囊、软胶囊）、液体、外用製剂、注射剂、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美药用辅料市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲药用辅料市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区药用辅料市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲药用辅料市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲药用辅料市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球药用辅料市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• BASF SE
• Origin Instruments Corporation
• Ashland Global Holdings
• DuPont de Nemours, Inc.
• Roquette Feres
• Evonik Industries AG
• Associated British Foods
• Archer Daniels Midland Company
• Lubrizol Corporation
• Croda International
• Kerry Group

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pharmaceutical Excipients Market is projected to increase from USD 8.97 Billion in 2025 to USD 12.19 Billion by 2031, reflecting a CAGR of 5.25%. These pharmacologically inactive substances are formulated alongside active pharmaceutical ingredients to facilitate drug delivery, improve stability, and ensure dosage consistency. Market growth is primarily supported by the rising prevalence of chronic diseases and an aging global population, which drive the demand for high-volume solid dosage medications. Additionally, the sustained expansion of the generic drug sector serves as a vital catalyst for volume growth. According to the Association for Accessible Medicines, generic and biosimilar medicines accounted for 90 percent of all prescriptions filled in the United States in 2024, demonstrating the critical role of cost-effective therapies in driving the demand for bulk formulation ingredients.

A significant challenge hindering market expansion is the growing complexity of regulatory compliance and supply chain transparency. Manufacturers are subject to rigorous standards regarding impurity limits, which necessitate extensive risk assessments and raw material tracing. These stringent requirements often result in higher operational costs and extended approval timelines, creating barriers for suppliers who must invest heavily to meet the evolving safety expectations of global health authorities.

Market Driver

The rapid expansion of the biopharmaceutical manufacturing sector is fueling demand for high-purity, functional excipients essential for parenteral delivery. Biologics, such as monoclonal antibodies, require specialized stabilizers and surfactants to maintain molecular integrity, shifting the market focus from traditional solid dosage fillers to advanced formulation ingredients. This structural trend toward complex therapies is accelerating rapidly; according to CPHI's 'Annual Report 2024' from September 2024, the industry is undergoing a major shift where approvals for complex molecules are projected to surpass small molecules, highlighted by the authorization of 17 biologics and nine peptide or oligonucleotide therapies among the 55 new drugs approved in 2023. This innovation is underpinned by substantial capital allocation; according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe in 2024, directly fueling the development pipeline for these novel drug delivery systems.

The expansion of the pharmaceutical contract manufacturing market further propels growth as drug developers increasingly outsource production to optimize costs and access specialized capabilities. Contract Development and Manufacturing Organizations (CDMOs) are becoming centralized purchasers, often requiring large volumes of multi-compendial excipients to meet diverse global regulatory standards. This consolidation of procurement is evident in the financial performance of leading service providers; according to Lonza's 'Annual Report 2023' released in March 2024, the company reported sales of CHF 6.7 billion, achieving a sales growth of 7.9 percent primarily driven by strong performance in its Biologics and Small Molecules divisions. As CDMOs expand their operational footprint, they necessitate a reliable supply chain of versatile excipients that facilitate streamlined manufacturing across varying dosage forms.

Market Challenge

The increasing complexity of regulatory compliance and supply chain transparency acts as a significant restraint on the Global Pharmaceutical Excipients Market. As international health authorities enforce stricter limits on impurities and demand rigorous raw material traceability, excipient manufacturers face a steep escalation in operational burdens. This compliance pressure forces suppliers to allocate substantial resources toward continuous risk assessments and validation protocols rather than production capacity expansion. Consequently, the time and capital required to bring compliant ingredients to market increase, creating barriers that disproportionately impact smaller suppliers and reduce the overall fluidity of the supply chain.

These regulatory bottlenecks directly impede market growth by disrupting the availability of essential formulation ingredients, leading to production stalls. According to the American Society of Health-System Pharmacists, the U.S. healthcare sector reported an all-time high of 323 active drug shortages in 2024, a crisis partially attributed to persistent manufacturing quality challenges and regulatory hurdles. This instability in the downstream manufacturing sector restricts the consistent volume demand for excipients, as finished dose manufacturers cannot maintain steady production schedules amidst such heightened compliance-driven disruptions.

Market Trends

The adoption of multifunctional and co-processed excipients is intensifying as manufacturers seek to streamline oral solid dosage production and reduce formulation complexity. These advanced, pre-formulated systems-such as ready-to-use film coatings and high-functionality binders-eliminate the need for multi-step blending, thereby enhancing operational efficiency and minimizing batch variability. This drive for manufacturing optimization is prompting major suppliers to expand their production footprints to ensure a reliable supply of these critical ingredients. According to Indian Chemical News in the July 2025 article 'Colorcon opens new film coating manufacturing facility in Malaysia', the company inaugurated a new 200,000 square-foot production plant specifically designed to support the growing regional demand for advanced coating systems and functional excipients.

Concurrently, the market is witnessing a decisive transition toward plant-based and clean label ingredients, driven by evolving patient preferences for non-animal derived formulations and strict dietary requirements. This shift is compelling excipient providers to pivot away from traditional animal-sourced materials like gelatin in favor of cellulose-based alternatives, such as HPMC, which offer comparable performance with broader consumer acceptance. Reflecting this strategic realignment, according to Nutritional Outlook in the October 2025 article 'ACG will invest $200 million in its first empty-capsule manufacturing facility in the US', the company announced a phased capital allocation of $200 million to establish a new facility capable of producing vegetarian hard-shell capsules to meet the rising need for clean label delivery forms in North America.

Key Market Players

• BASF SE
• Origin Instruments Corporation
• Ashland Global Holdings
• DuPont de Nemours, Inc.
• Roquette Feres
• Evonik Industries AG
• Associated British Foods
• Archer Daniels Midland Company
• Lubrizol Corporation
• Croda International
• Kerry Group

Report Scope

In this report, the Global Pharmaceutical Excipients Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Excipients Market, By Product

• Organic Chemicals
• Oleochemicals(Fatty Alcohols, Metal Stearates, Glycerin, Other)
• Carbohydrates(Sugars, Alcohol, Starches)
• Petrochemicals
• Proteins
• Calcium Phosphate
• Metal Oxides
• Halites
• Calcium Carbonate
• Calcium Sulphate
• Others

Pharmaceutical Excipients Market, By Functionality

• Fillers & Diluents
• Suspending & Viscosity Agents
• Coating Agents
• Binders
• Flavoring Agents & Sweeteners
• Disintegrants
• Colorants
• Lubricants & Glidants
• Preservatives
• Emulsifying Agents
• Others

Pharmaceutical Excipients Market, By Formulation

• Oral Formulations
• Tablets
• Capsules(Hard-gelatin Capsules, Soft-gelatin Capsules)
• Liquid Formulations
• Topical Formulations
• Parenteral Formulations
• Other

Pharmaceutical Excipients Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Excipients Market.

Available Customizations:

Global Pharmaceutical Excipients Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Excipients Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Organic Chemicals, Oleochemicals(Fatty Alcohols, Metal Stearates, Glycerin, Other), Carbohydrates(Sugars, Alcohol, Starches), Petrochemicals, Proteins, Calcium Phosphate, Metal Oxides, Halites, Calcium Carbonate, Calcium Sulphate, Others)
  • 5.2.2. By Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, Others)
  • 5.2.3. By Formulation (Oral Formulations, Tablets, Capsules(Hard-gelatin Capsules, Soft-gelatin Capsules), Liquid Formulations, Topical Formulations, Parenteral Formulations, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Excipients Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Functionality
  • 6.2.3. By Formulation
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Excipients Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Functionality
      • 6.3.1.2.3. By Formulation
  • 6.3.2. Canada Pharmaceutical Excipients Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Functionality
      • 6.3.2.2.3. By Formulation
  • 6.3.3. Mexico Pharmaceutical Excipients Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Functionality
      • 6.3.3.2.3. By Formulation

7. Europe Pharmaceutical Excipients Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Functionality
  • 7.2.3. By Formulation
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Excipients Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Functionality
      • 7.3.1.2.3. By Formulation
  • 7.3.2. France Pharmaceutical Excipients Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Functionality
      • 7.3.2.2.3. By Formulation
  • 7.3.3. United Kingdom Pharmaceutical Excipients Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Functionality
      • 7.3.3.2.3. By Formulation
  • 7.3.4. Italy Pharmaceutical Excipients Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Functionality
      • 7.3.4.2.3. By Formulation
  • 7.3.5. Spain Pharmaceutical Excipients Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Functionality
      • 7.3.5.2.3. By Formulation

8. Asia Pacific Pharmaceutical Excipients Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Functionality
  • 8.2.3. By Formulation
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Excipients Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Functionality
      • 8.3.1.2.3. By Formulation
  • 8.3.2. India Pharmaceutical Excipients Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Functionality
      • 8.3.2.2.3. By Formulation
  • 8.3.3. Japan Pharmaceutical Excipients Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Functionality
      • 8.3.3.2.3. By Formulation
  • 8.3.4. South Korea Pharmaceutical Excipients Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Functionality
      • 8.3.4.2.3. By Formulation
  • 8.3.5. Australia Pharmaceutical Excipients Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Functionality
      • 8.3.5.2.3. By Formulation

9. Middle East & Africa Pharmaceutical Excipients Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Functionality
  • 9.2.3. By Formulation
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Excipients Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Functionality
      • 9.3.1.2.3. By Formulation
  • 9.3.2. UAE Pharmaceutical Excipients Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Functionality
      • 9.3.2.2.3. By Formulation
  • 9.3.3. South Africa Pharmaceutical Excipients Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Functionality
      • 9.3.3.2.3. By Formulation

10. South America Pharmaceutical Excipients Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Functionality
  • 10.2.3. By Formulation
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Excipients Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Functionality
      • 10.3.1.2.3. By Formulation
  • 10.3.2. Colombia Pharmaceutical Excipients Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Functionality
      • 10.3.2.2.3. By Formulation
  • 10.3.3. Argentina Pharmaceutical Excipients Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Functionality
      • 10.3.3.2.3. By Formulation

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Excipients Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BASF SE
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Origin Instruments Corporation
• 15.3. Ashland Global Holdings
• 15.4. DuPont de Nemours, Inc.
• 15.5. Roquette Feres
• 15.6. Evonik Industries AG
• 15.7. Associated British Foods
• 15.8. Archer Daniels Midland Company
• 15.9. Lubrizol Corporation
• 15.10. Croda International
• 15.11. Kerry Group

16. Strategic Recommendations

17. About Us & Disclaimer